Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| Safety and Feasibility of CD19 Chimeric Antigen Receptor (CAR) T Cells In Adults with CD19 Positive Relapsed and Refractory Acute Lymphoblastic Leukemia or Lymphoma | KAIMRC | Completed | CD19-CART | 1b | RC20/446/R | NGHA-R |
| S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer | SWOG (Southwest Oncology Group) | Ongoing | CARVEDILOL | 3 | S1501 | KFSH & RC-R |
| RELATED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SYMPTOMATIC SICKLE CELL DISEASE: A PROSPECTIVE STUDY | King Faisal Specialist Hospital and Research Centre | Ongoing | HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) | 3 | 2191237 | KFSH&RC-R |
| Re-EValuating the Inhibition of Stress Erosions and prophylaxis against gastrointestinal bleeding in the critically ill | KAIMRC | Ongoing | pantoprazole | 3 | CT19/009/R | King Abdulaziz Medical City NG (Riyadh) |
| Re-challenge therapy with chemotherapy and panitumumab in metastatic colorectal cancer patients treated with an anti-EGFR therapy in 1st line treatment: a phase II multicentre study. | King Abdullah Medical City, Holy Capital | Ongoing | PANITUMUMAB | 2 | 19-504 | KAMC |
| Randomized, two-way, two- period, single oral dose, open- label, crossover, bioequivalence study to compare Diclofenac Potassium powder for oral solution (50 mg diclofenac potassium) manufactured by Riyadh Pharma versus Catafast® powder for oral solution (50 mg diclofenac potassium) manufactured by Mipharm S.p.A., in healthy subjects under fasting condition. | Saudi Ajal | Ongoing | DICLOFENAC POTASSIUM | 1 | 42856 | Saudi Ajal |
| Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia | Hikma | Rejected | Dasatinib | 2 | LPI-JOR-LEB-KSA-TUN- | KFSH & RC - R |
| "Randomized, Open Label, Non-inferiority Study of Micafungin Versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients " | Astellas | Completed | Micafungin | 3b | 9463EC0001 | NGHA-R |
| "Randomized, Embedded, Multifactorial Adaptive Platform trial for Community- Acquired Pneumonia (REMAP-CAP)" | KAIMRC | Ongoing | Ceftriaxone - Piperacillin Tazobactam - Azithromycin - Interferon β1-a - Hydrocortisone sodium suc... - Hydroxychloroquine - OSELTAMIVIR - Lopinavir-Ritonavir | 3 | CT20/001/R | NGHA-R |
| Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Solifenacin succinate film-coated tablets (10 mg solifenacin succinate) versus Vesicare® film-coated tablets (10 mg solifenacin succinate), in healthy subjects under fasting condition. | SPIMACO ADDWAEIH | Ongoing | solifenacin succinate | 1 | 42767 | Saudi Ajal |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.